Blog - Litchlab

EN

CN

{$ImageUrl,alt}

Blog

Home>Blog

FBSH-EDC Hydrogel: An Innovative Material from Fetal Bovine Skin Tissue to Skin Repair

FBSH-EDC Hydrogel: An Innovative Material from Fetal Bovine Skin Tissue to Skin RepairIn the field of tissue engineering and regenerative medicine, naturally derived hydrogels have attracted significant attention due to their biocompatibility and soft structur...

Comprehensive Analysis of Liposome Types: Diversified Solutions for Vaccine Delivery

Comprehensive Analysis of Liposome Types: Diversified Solutions for Vaccine DeliveryLiposomes, as crucial carriers for vaccine delivery, possess unique structural and functional characteristics that enable them to meet the complex needs of various vaccines. Fr...

Breakthrough of Liposome Technology in Cancer Therapy: FDA Approval of Irinotecan Liposome for First-Line Treatment of Metastatic Pancreatic Adenocarcinoma

Breakthrough of Liposome Technology in Cancer Therapy: FDA Approval of Irinotecan Liposome for First-Line Treatment of Metastatic Pancreatic Adenocarcinoma In May 2024, the U.S. Food and Drug Administration (FDA) announced the approval of irinotecan lipos...

mRNA Vaccines and Lipid Nanoparticle Lyophilization Technology: Breakthroughs in Innovative Delivery Systems in Vaccine Development

mRNA Vaccines and Lipid Nanoparticle Lyophilization Technology: Breakthroughs in Innovative Delivery Systems in Vaccine Development Driven by the COVID-19 pandemic, mRNA vaccines and lipid nanoparticle (LNP) delivery systems have become key technologies i...

Say Goodbye to Traditional Flu Vaccines! SM-102 Powers a New Generation of mRNA Immune Solutions

In recent years, mRNA technology has been increasingly applied in vaccine and drug development. Following the COVID-19 pandemic, the potential of mRNA platforms has gradually expanded to major infectious diseases such as seasonal influenza, RSV, and CMV. Among...

Disrupting the HPV Vaccine Landscape! R-DOTAP Boosts Peptide Vaccine Immunity, Litchlab Achieves Kilogram-Scale Production

In recent years, therapeutic vaccines targeting virus-associated cancers have gained growing attention, with human papillomavirus (HPV)-induced cervical cancer and oropharyngeal cancer standing out as major focus areas. Peptide-based vaccines, due to their hig...

From Injection to “Patch-on”: Chitosan/PVA Microneedle Technology Brings New Imagination for Vaccines

With the continuous advancement of vaccine technologies, the traditional injection approach is increasingly revealing its limitations in terms of safety, compliance, and distribution efficiency. Needle phobia, strained medical resources, and a strong reliance ...

SM-102 Lipid Delivery with Litchlab Services — Accelerating the Development of Tetravalent Dengue mRNA Vaccines

Dengue fever is caused by four distinct serotypes of the dengue virus: DENV-1, DENV-2, DENV-3, and DENV-4. It is the most widespread mosquito-borne viral disease globally. Due to the risk of antibody-dependent enhancement (ADE), the development of a tetravalen...

Softer, More Healing: MCC/Alginate Composite Hydrogels Are Reshaping Wound Repair

BackgroundWith the continuous advancement of modern medical technology, the performance requirements for wound management and tissue repair materials are steadily increasing. Traditional dressings often suffer from poor adherence, limited breathability, and lo...

From siRNA to mRNA: Choosing the Optimal Lipid Delivery Material (SM-102, ALC-0315, MC3)

With the rapid rise of nucleic acid therapeutics and mRNA vaccines, lipid nanoparticles (LNPs) have emerged as the most critical in vivo delivery platform. Among them, SM-102, ALC-0315, and MC3 are the most widely used ionizable lipids, each with unique advant...

上一页 1 2 3 4 5 下一页